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Introduction
Charcot-Marie-Tooth (CMT) disease is a group of genetically 
heterogenous neuropathies that comprise the commonest dis-
orders of the peripheral nervous system (PNS)1. CMT4F is a 
demyelinating autosomal recessive type caused by about 24 
different mutations in the Periaxin (PRX) gene that manifests with 
motor and sensory disturbances2–13. Periaxin forms a complex 
with Dystrophin-Related Protein 2 (Drp2) and Dystroglycan 
(Dag) and this Prx/Drp2/Dag complex assembles adhesive appo-
sitions between the abaxonal surface of PNS myelin and the 
Schwann cell plasma membrane that are surrounded by 
cytoplasm-filled Cajal bands14,15. The appositions and Cajal 
bands are lost either in the complete absence of Periaxin or 
Drp2, or if the interaction between these two proteins is pre-
vented, and this results in disruption of the myelin sheath14–16. By 
comparison with Drp2, loss of Periaxin leads to a more severe 
phenotype in mice, involving more extensive demyelination and 
reductions in internodal length associated with reduced nerve 
conduction velocities, all of which are consistent with the distinct 
clinical severities observed in man14,15,17,18.
An intriguing aspect of the Prx gene is that more than 90% 
of the protein is encoded by its terminal exon19. Since most 
CMT4F nonsense or frame-shift mutations are located in this 
exon, the corresponding mRNAs that encode premature stop 
codons are likely to escape nonsense-mediated RNA decay 
and result in the production of a mutant version of the Periaxin 
protein20. Proof that this is the case has been obtained using 
sural nerve biopsies from two families harbouring distinct 
mutations8,9. One of these mutations has been shown to result in 
the production of C-terminally truncated Periaxin lacking the last 
391 amino acids4,7,9,21. Since the N-terminus of Periaxin has 
been primarily implicated in the assembly of the Prx/Drp2/Dag 
complex thus far15,16,18, we have explored whether loss of the 
C-terminus might also contribute to the formation and/or 
stabilization of the membrane appositions responsible for the 
construction of Cajal bands.
Methods
Mice
All animal work conformed to United Kingdom legislation (Sci-
entific Procedures) Act 1986, and to the University of Edinburgh 
Ethical Review Committee policy. The production of 
transgenic mice, expressing the cDNA encoding full-length 
mouse Periaxin (PrxTg) under the control of a rat Mpz promoter 
and generated by RT-PCR with a FLAG tag fused at its 5´ end, 
has been described previously15. A transgenic line expressing a 
FLAG-tagged, truncated mouse Periaxin lacking the C-terminal 
391 amino acids was generated in similar fashion (ΔCPrxTg). 
The presence of the N-terminal FLAG tag allowed for the 
unambiguous identification of transgenic proteins. After 
backcrossing to C57BL/6 (Harlan) for at least six generations, 
these mice were interbred with Prx-/- mice so that the transgenes 
were expressed on a Periaxin-null background as previously 
described15. Males and females were used for all experi-
ments and the age and number of the animals are described in 
the figure legends. For Western blotting and immunocyto-
chemistry animals were sacrificed humanely by a schedule 1 
method (cervical dislocation followed by exsanguination) in 
compliance with the UK Animal (Scientific Procedures) Act, 
1986. For electron microscopy mice were anaesthetized with 
halothane (as approved for PPL P0F4A25E9 under the UK 
Animal (Scientific Procedures) Act, 1986) and perfused with 
fixative as described15. All mice were housed in individual ven-
tilated cages to ensure optimal health status and the health 
status of sentinel mice was routinely screened every six months.
Western blotting, immunocytochemistry, histology and 
electrophysiology
Western blotting of peripheral nerve lysates prepared from 
sacrificed mice was using rabbit polyclonal antibodies directed 
at the N-terminus (1:20,000) or sheep polyclonal antibodies 
(1:10,000) to the C-terminus of mouse Periaxin (5 μg lysate 
protein) and rabbit anti-Drp2 polyclonal antibodies (1:3000) 
(15 μg lysate protein)16,19. Rabbit polyclonal antibodies versus 
γ-Actin used for Western Blotting (1:10,000) were raised 
against a peptide comprising the N-terminus of γ-Actin with an 
additional C-terminal cysteine (EEEIAALVIDNGSGC) coupled 
to Keyhole Limpet hemocyanin as described19. Immunostaining 
of teased peripheral nerve fibres with rabbit anti-Drp2 polyclonal 
antibodies (1:200)16, and light microscopy of toluidine blue-stained 
transverse sections of nerve were all performed using quadri-
ceps nerves as previously described, and abnormal profiles were 
evaluated by examining a minimum of 491 myelinated axons 
per animal15,18. Internodal lengths (a minimum of 96 per animal) 
and nerve conduction velocities (a minimum of 2 per animal) 
were measured as described previously14.
Cross-linking, immune precipitation of periaxin and mass 
spectrometry
Formaldehyde crosslinking prior to immuneprecipitation has been 
described22. Freshly prepared 4% paraformaldehyde in 100 mM 
Sorenson’s phosphate buffer pH 7.4 was prepared and frozen in 
aliquots. Sciatic and quadriceps nerves from each mouse were 
desheathed and teased in PBS containing phosphatase inhibi-
tors. After removal of the PBS, a 0.5% formaldehyde solution 
in 100 mM phosphate buffer (1 ml) was added and the nerves 
were incubated for 9 min with agitation at room temperature. 
After sedimentation by centrifugation for 1 min, 0.5 ml of 1.5 M 
glycine was added to the pellet. Nerves were further washed 
at 4°C with 1.25 M glycine and PBS, followed by a final 
wash with PBS. Nerves were then lysed in 50 μl of 2% SDS and 
incubated at 65°C for 10 min. Lysates were collected and stored 
at -80°C.
Periaxin was immuneprecipitated from the nerves of 2 mice 
(100 μl) after first warming lysates to 55°C for 2 min followed 
by dilution with 400 μl of Solution A as previously described23. 
The diluted lysate was incubated overnight with washed FLAG 
agarose beads (20 μl) (Sigma A2220) at 4°C with rotation. 
The beads were extensively washed with Solution A without 
Triton X-100, resuspended with 30 μl NuPage sample buffer 
containing DTT (Invitrogen), and warmed at 65°C for 10 min. 
The sample was briefly electrophoresed in NuPage gel and 
after staining with SimplyBlue SafeStain (Invitrogen) accord-
ing to the manufacturer’s instructions, the high molecular 
weight cross-linked bands were excised and processed for mass 
spectrometry.
Page 3 of 10
Wellcome Open Research 2018, 3:20 Last updated: 24 APR 2018
Three separate samples were analysed for both PrxTg/Prx-/- 
and ΔCPrxTg/Prx-/- mice (a total of 6 mice per genotype). After 
tryptic digestion of the gel bands, peptide extracts were dried, 
resuspended in MS-loading buffer (0.5% trifluoroacetic acid 
in water) and filtered using Millex filters before HPLC-MS 
analysis. Analysis was performed using an online system of a 
nano-HPLC (Dionex Ultimate 3000 RSLC, Thermo-Fisher) 
coupled to a QExactive mass spectrometer (Thermo-Fisher) 
with a 300μm × 5mm pre-column (Acclaim Pepmap, 5μm parti-
cle size) joined with a 75μm × 50cm column (Acclaim Pepmap, 
3μm particle size). Samples were run using a 90 min gradient and 
data from MS/MS spectra was searched using MASCOT against 
a  Uniprot Mouse database. Progenesis (Nonlinear Dynamics) 
was used for label-free quantitation. Search results were exported 
using a significance threshold (p-value) of less than 0.05 and 
a peptide score cut off of 20. All samples were normalized for 
protein content.
Statistical analysis
Prism 6 (GraphPad Software, version 6.0g) was used to evalu-
ate statistical significance using an unpaired t-test with Welch’s 
correction and to generate all graphs. 
Results
Proteins with predicted sizes were expressed from the full length 
and truncated Prx transgenes in a Periaxin-null background 
(Figures 1A and 1B). Both proteins were detected by Western 
blotting using an antibody directed to the N-terminus, whereas 
Figure 1. C-terminal truncation of Periaxin disrupts appositions between the abaxonal surface of the myelin sheath and the 
Schwann cell plasma membrane formed by the Prx/Drp2/Dag complex. (A) Diagram showing the proteins encoded by the transgenes 
PrxTg/Prx-/- and ΔCPrxTg/Prx-/- respectively. The locations of the FLAG tag (FL), and PDZ, basic, repeat and acidic domains are also 
shown, of which the PDZ and basic domains are known to be essential for apposition assembly16,18,19,23. (B) Western blotting with an 
antibody directed to the N-terminus of Periaxin detects the wild-type (WT) protein and both transgenic proteins when expressed on a 
Periaxin-null background, whereas only the full length WT and transgenic protein was detected by an antibody against the C-terminus of 
Periaxin. Peripheral nerve lysates were from P21 animals. γ-Actin is the loading control. (C) Western blots showing decreases in the level 
and extensive dephosphorylation (lower band) of Drp2 in ΔCPrxTg/Prx-/- mice. The extent of Drp2 dephosphorylation increased from P21 
to P50. (D) Drp2-positive appositions were sparse but detectable by immunofluorescence at P21 but by P50 they were gone, and this 
coincides with the greater degree of Drp2 dephosphorylation at this later age (see C). Size marker = 10 μm.
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only the full length protein was detected by an antibody against 
the C-terminus of the wild-type protein (Figure 1B). Although 
the levels of Periaxin’s binding partner Drp2 were normal 
in the quadriceps nerves of control PrxTg/Prx-/- mice, there was 
a substantial loss of Drp2 in ΔCPrxTg/Prx-/- mice (Figure 1C). 
This reduction in the level of Drp2 in the peripheral nerves of 
ΔCPrxTg/Prx-/- mice was reflected by a 2.6 fold reduction in 
the absolute value of Drp2 in ΔCPrxTg/Prx-/- mice by mass 
spectrometric analysis. Furthermore, there was a shift with 
age to more of the dephosphorylated lower band of Drp2, 
which is known to be associated with dissociation from the 
Prx/Drp2/Dag complex (Figure 1C)15. From previous work15, 
we know that these changes in Drp2 levels and increased 
dephosphorylation should have structural consequences for the 
assembly and stabilization of appositions at the Schwann cell 
plasma membrane, and this is what we see (Figure 1D).
Histological analysis of mouse peripheral nerves with mutations 
in either the Prx or Drp2 genes have previously revealed 
abnormal profiles of myelinated axons in transverse sections14,15,18. 
This was also observed in the ΔCPrxTg/Prx-/- mice (Figure 2A 
and B). Further, even at P21 when mutant nerves displayed a 
modest increase in abnormal profiles, their internodal lengths were 
significantly shorter (Figure 2C). As has been argued elsewhere, 
this is likely to be the primary cause of the reduced nerve conduc-
tion velocities observed in mutant nerves at P2114,18 (Figure 2D).
Figure 2. C-terminal truncation of Periaxin destabilizes myelin, and reduces internodal length and nerve conduction velocity in the 
PNS. (A) Light microscopy of transverse sections from control (PrxTg/Prx-/-) and mutant (ΔCPrxTg/Prx-/-) quadriceps nerves at P90 show 
extensive abnormal profiles of myelinated axons. Size marker = 10 μm. (B) There is a progressive increase in the number of abnormal profiles 
from P21 to P90 compared to control nerves. Mean values ± SEM, n = 3–5. (C) Internodal lengths of mutant nerves are significantly reduced 
at P21. Mean values ± SEM, n = 4–5. (D) Nerve conduction velocities of mutant nerves are significantly reduced at P21. Mean values ± SEM, 
n = 6–8. *P < 0.05; ***P < 0.0005; ns, not significant.
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Discussion
CMT4F disease caused by C-terminal truncations of Periaxin has 
been difficult to explain mechanistically since the two domains 
that have been well-characterised as essential for the forma-
tion of the Prx/Drp2/Dag complex, namely the homodimerizing 
PDZ domain and the basic, Drp2 interaction domain, are both 
at the N-terminus of the protein16,18 (Figure 1A). In an effort to 
understand why loss of the Periaxin C-terminus should cause 
disease we generated transgenic mice expressing either full 
length Periaxin or a truncated form that corresponds to the 
mutant protein in some patients, and we expressed these pro-
teins in a Periaxin-null background. To our surprise, myelinating 
Schwann cells expressing mutated Periaxin possessed 
considerably less Drp2 and the protein was significantly 
dephosphorylated. Both factors would be expected to 
attenuate the formation of Prx/Drp2/Dag-rich adhesive apposi-
tions and thereby compromise the formation of Cajal bands, 
which, in turn, should destabilize the myelin sheath. This is what 
we observed, and it appeared to get worse with age.
Loss of Drp2, and the accompanying disruption of Cajal bands, 
has a much less severe phenotype in both mice and man than 
loss of Periaxin11,12,15–17. In mice lacking Drp2 internodal 
lengths are unaffected, conductions speeds are normal and 
demyelination is much less extensive15. Therefore, Periaxin 
apparently has other roles in Schwann cell biology in addition 
to promoting the assembly of Cajal bands. The present study 
supports this view and identifies the C-terminus of the protein as 
a contributor to the regulation of Schwann cell growth, which is 
crucial to ensure normal conduction speeds14.
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